Scios Inc. company, a subsidiary of health care giant Johnson & Johnson, develops treatments targeting cardiovascular disease. Its flagship product Natrecor is an intravenously administered drug approved by the FDA for treating patients with acute heart failure who also experience shortness of breath with minimal activity. When the drug was introduced in 2001, it was the first new treatment for heart failure in more than 14 years. The drug is not without controversy, about both its long-term health effects and the company's marketing of it. Scios maintains the drug is safe and has launched a large clinical trial.

GelStat Corporation engages in the development and marketing of over the counter and other nonprescription consumer health care products for pain and inflammation. It markets GelStat Migraine, a homeopathic drug, for the treatment of migraine and migraine-like headaches, as well as GelStat Arthritis, a sublingual dissolving tablet for the treatment of pain and associated symptoms of arthritis. The company is also developing other products that are in the final stages of development, which include GelStat Sinus for the remedy of nasal and/or sinus congestion, irritation, pressure, and sinus headache; and GelStat Sleep for promoting restful sleep. The company sells its products to regional and national retailers, wholesalers, specialty distributors, and catalog merchandisers in the United States directly and through sales brokers. GelStat Corporation is based in Bloomington, Minnesota.

Naturewell, Incorporated does not have significant operations. Naturewell company intends to seek business opportunities, including an acquisition or merger with an operating business. Previously, it engaged in the research and development of proprietary healthcare products for various conditions, which comprise primary migraine medication, MIGRASPRAY. Naturewell company is based in San Diego, California.

Callisto Pharmaceuticals, Inc. was founded in 1996 and is headquartered in New York, New York. Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses primarily on the development of drugs to treat gastrointestinal disorders and diseases, rheumatoid arthritis, neuroendocrine cancer, and acute leukemia. The company has three drugs in development, which include SP-304, a guanylyl cyclase C receptor agonist for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome, which has completed Phase I clinical trial; Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activities, which is in Phase II development for advanced carcinoid cancer; and L-Annamycin, a novel compound from the anthracycline family of proven anti-cancer drugs for the treatment of leukemia. It also focuses on the development of Atiprimod for the treatment of rheumatoid arthritis. The company has license agreements with AnorMED Inc. to research, develop, sell, and commercialize the Atiprimod patent rights; and the University of Texas M.D. Anderson Cancer Center to develop and commercialize the L-Annamycin patent rights.

Forbes Medi-Tech has an answer for folks wanting to lower their cholesterol by changing their diet. The firm makes Reducol, a dietary supplement ingredient that reduces LDL, the "bad" cholesterol associated with increased risk of heart disease. It sells the ingredient to food and nutritionals companies that incorporate it into their products. Pharmavite uses Reducol in its Cholest-Off supplement, and foodmakers in Europe use it in items such as yogurt, milk, and bread. Until 2008 Forbes Medi-Tech also had a drug development operation, which was testing pharmaceutical candidates to treat high cholesterol and metabolic conditions; however, it has divested those operations to focus on its Reducol business.

diaDexus, Inc. was founded in 1997 and is based in South San Francisco, California. diaDexus, Inc., a biotechnology company, engages in the discovery, development, and commercialization of in vitro diagnostic products to address the medical needs in the cardiovascular field. The company develops The PLAC Test, a blood test to aid in assessing risk for coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. Its product measures lipoprotein-associated phospholipase A2 (Lp-PLA2), which is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. The company’s PLAC Test is available as an ELISA assay that runs on an automated micropate system, as well as in the form of immunotarbidimetric technology that runs on common clinical chemistry analyzers used in clinical reference laboratories, hospitals, and physician office laboratories.

Protalex, Inc. company was founded in 1999 and is headquartered in New Hope, Pennsylvania. Protalex, Inc., a development stage company, engages in the development of biopharmaceutical drugs for the treatment of autoimmune and inflammatory diseases in the United States. Protalex company targets the autoimmune diseases rheumatoid arthritis and idiopathic thrombocytopenic purpura. Its lead compound, PRTX-100, is a purified form of the Staphylococcal bacterial protein known as Protein A that has the ability to bind to and to down regulate activation of human B-lymphocytes and macrophages, which are key cells mediating inflammation in certain autoimmune diseases.

Abaxis was founded in 1989 and is headquartered in Union City, California. Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements in the medical and veterinarian markets worldwide. Its products include Point-Of-Care Blood Chemistry Analyzer, which performs a panel of 14 tests on human patients and 13 tests on veterinary patients marketed under the Piccolo xpress and Piccolo Classic names in the human medical market and under the VetScan VS2 and VetScan Classic names in the veterinary market. The company's products also include Reagent Discs that handle various technical steps of blood chemistry testing automatically; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, which offer blood count analysis for veterinary applications. In addition, its products comprise VetScan VSpro that assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular disease, hepatic disease and monitoring therapy, and progression of disease states; and VetScan Canine Heartworm Rapid Test, a test for the detection of dirofilaria immitis in canine whole blood, serum, or plasma. Further, Abaxis's products consist of Orbos Discrete Lyophilization Process, which allows the production of active chemical ingredient in the form of a soluble bead, as well as involves in flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The company markets and sells its products through a direct sales force in the United States and through independent distributors.

Dragon Pharmaceutical is looking to build a pharmaceutical empire in the PRC. Headquartered in Canada, the company has production facilities within mainland China that manufacture active pharmaceutical ingredients (APIs), intermediates, and finished formulations. It sells its bulk APIs and intermediates, which are used in antibiotic formulations, both in China and internationally (mainly in India). Its finished products (sold only in China) are primarily injectable cephalosporin antibiotics. In 2007 Dragon Pharmaceutical divested its biotech division in order to focus on its core antibiotic operations. CEO Yanlin Han holds nearly half of the company's stock and is seeking to buy the balance.

NeoPharm, Inc. was founded in 1990 and is headquartered in Lake Bluff, Illinois. NeoPharm, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases primarily in the United States. Its products include LEP-ETU, which is in Phase II trial for the treatment of breast and ovarian cancer; LE-DT that is in Phase I trial for the treatment of various forms of cancer; and LE-rafAON, which completed preclinical studies to treat pancreatic cancer. The company has a co-operative research and development agreement with the National Institute of Neurological Diseases and Stroke for research on a therapeutic agent for untreatable brain diseases in humans. NeoPharm would provide its proprietary drug, Cintredekin Besudotox (IL13-PE38QQR), and technical resources to study its effects in various brain cancers in humans. Its IL13-PE38QQR also completed preclinical studies for the treatment of idiopathic pulmonary fibrosis and asthma. The company was formerly known as OncoMed, Inc. and changed its name to NeoPharm, Inc. in March 1995.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.